PT90959A - Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos - Google Patents

Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos

Info

Publication number
PT90959A
PT90959A PT90959A PT9095989A PT90959A PT 90959 A PT90959 A PT 90959A PT 90959 A PT90959 A PT 90959A PT 9095989 A PT9095989 A PT 9095989A PT 90959 A PT90959 A PT 90959A
Authority
PT
Portugal
Prior art keywords
derivs
new
cyclododecane
aza
tetra
Prior art date
Application number
PT90959A
Other languages
English (en)
Other versions
PT90959B (pt
Inventor
Jaime Simon
Joseph R Garlich
Kenneth Mcmillan
David A Wilson
William J Kruper Jr
Richard K Frank
Roberta C Cheng
William A Fordyce
William F Goeckeler
Sharon Baughman
Garry Kiefer
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of PT90959A publication Critical patent/PT90959A/pt
Publication of PT90959B publication Critical patent/PT90959B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
PT90959A 1988-06-24 1989-06-23 Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos PT90959B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21149688A 1988-06-24 1988-06-24

Publications (2)

Publication Number Publication Date
PT90959A true PT90959A (pt) 1989-12-29
PT90959B PT90959B (pt) 1995-05-04

Family

ID=22787153

Family Applications (1)

Application Number Title Priority Date Filing Date
PT90959A PT90959B (pt) 1988-06-24 1989-06-23 Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos

Country Status (6)

Country Link
US (1) US5652361A (pt)
CN (2) CN1033030C (pt)
AU (1) AU3705889A (pt)
BR (2) BR1100580A (pt)
PT (1) PT90959B (pt)
ZA (1) ZA894792B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68901924T2 (de) * 1988-01-26 1992-12-10 Nycomed As Paramagnetische verbindungen.
WO1989012631A1 (en) * 1988-06-24 1989-12-28 The Dow Chemical Company Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US6139603A (en) * 1989-02-22 2000-10-31 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Process for recovering oxygen
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
DE19652387A1 (de) * 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
US6231832B1 (en) 1998-03-23 2001-05-15 Brookhaven Science Associates Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
DE60140773D1 (de) 2000-08-18 2010-01-21 Dyax Corp Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
US6670456B2 (en) 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP1534739A4 (en) * 2002-01-18 2006-05-31 Bristol Myers Squibb Co IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS THAT INTERACT WITH TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
EP1531848A4 (en) * 2002-06-10 2007-03-28 Vaccinex Inc DIFFERENTIAL EXPRESSED GENE IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDE
JP5042631B2 (ja) * 2003-12-04 2012-10-03 バクシネックス インコーポレーティッド アポトーシス腫瘍細胞上に露出した細胞内抗原をターゲッティングすることによって腫瘍細胞を死滅させる方法
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
JP2008502726A (ja) 2004-06-09 2008-01-31 ケレオス インコーポレーティッド キレートモノアミドの親油性誘導体
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
TWI397535B (zh) 2006-03-21 2013-06-01 Genentech Inc 包含α5β1拮抗劑之組合治療
WO2007126730A1 (en) * 2006-03-29 2007-11-08 Isotherapeautics Group Llc Radionuclide therapy for urinary bladder cancer
WO2007149586A2 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
GB0624587D0 (en) * 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
CA2682064C (en) * 2007-03-27 2013-09-24 Radiomedix Inc. Compositions for targeted imaging and therapy
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
JP2012510477A (ja) * 2008-12-02 2012-05-10 ザ ユニバーシティー オブ メルボルン 放射性医用薬剤としての窒素含有大環状結合体
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
SG10201609416XA (en) 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
WO2013003912A1 (en) 2011-07-07 2013-01-10 Australian Nuclear Science And Technology Organisation Cryptate compounds
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
AU2015266664B2 (en) 2014-05-30 2020-04-30 Shanghai Henlius Biotech, Inc. Anti-epidermal growth factor receptor (EGFR) antibodies
CN106573961B (zh) 2014-06-20 2022-01-04 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
SG10201913158PA (en) 2015-04-03 2020-02-27 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
RU2752832C2 (ru) 2016-09-16 2021-08-09 Шанхай Хенлиус Байотек, Инк. Анти-pd-1 антитела
EP3568468A4 (en) 2017-01-12 2020-12-30 Eureka Therapeutics, Inc. RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
MY201065A (en) 2017-04-26 2024-02-01 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN109384737A (zh) * 2017-08-04 2019-02-26 天津科伦药物研究有限公司 一种四氮杂环钇络合物及其制备方法和应用
BR112020014591A2 (pt) 2018-03-14 2020-12-01 Beijing Xuanyi Pharmasciences Co., Ltd. anticorpos anticlaudina 18.2
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
SE8301395L (sv) * 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
EP0232751B1 (en) * 1986-01-23 1991-09-11 E.R. Squibb & Sons, Inc. 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds

Also Published As

Publication number Publication date
CN1033030C (zh) 1996-10-16
PT90959B (pt) 1995-05-04
US5652361A (en) 1997-07-29
ZA894792B (en) 1991-04-24
BR1100574A (pt) 2000-06-06
AU3705889A (en) 1990-01-04
BR1100580A (pt) 2000-06-06
CN1044095A (zh) 1990-07-25
CN1050836C (zh) 2000-03-29
CN1109469A (zh) 1995-10-04

Similar Documents

Publication Publication Date Title
PT90959A (pt) Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos
Burrows et al. Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro
ATE139122T1 (de) Von mhc gestützte konjugate zur verwendung bei der steigerung der autoimmunität
AU4688589A (en) A method for treatment of endotoxic shock in a mammal
ES2080838T3 (es) Conjugados de anticuerpos especificos del receptor de transferrina y agentes neurofarmaceuticos.
EP0331034A3 (en) Functionally specific antibodies
AU2387088A (en) Cationized antibodies for delivery through the blood-brain barrier
AU5437590A (en) Method for enhancing transmembrane transport of exogenous molecules
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
EP0568645A4 (en) Mixed specificity fusion proteins
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
AU7366687A (en) Coupling agents for radiolabeling proteins
GB9206422D0 (en) Antibody preparation
CA2007463A1 (en) Dispensing devices powered by hydrogel
KR900701326A (ko) 감염성 및 염증성 병변의 검색 및 치료법
NO20001962L (no) Terapeutisk anvendelse av kinolinderivater
AU585253B2 (en) Carrier material for use in immune determinations
KR920703037A (ko) 심근 불안정과 관련된 저혈압증, 구기, 서맥의 치료를 위한 5-ht₃길항질
HU9300125D0 (en) Medical preparative for transdermal application of active agents
JPS6456697A (en) Viii factor bonded domain of von willebrand's factor
AU2724492A (en) Antibodies in immunosuppression
ES2182833T3 (es) Agentes antitromboticos multimeros polivalentes.
EP0504327A4 (en) Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof
AU8555291A (en) Delivery of agents
EP0046915A3 (en) A method for the recovery of a peptide-containing compound, and a means for the realization of the method

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19941020

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20091020